Mobile

A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combi...

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-002254-59

A phase 3, open label, randomised, parallel group study to compare the effect on prevention and resolution of treatment related adverse events of a simplified, once daily regimen of a fixed dose combination tablet of emtricitabine and tenofovir DF versus twice daily co-formulated zidovudine and lamivudine (Combivir®) or zidovudine and lamivudine, in virologically suppressed, HIV infected patients taking efavirenz

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine if switching from Combivir® or AZT +3TC to a fixed-dose tablet of FTC/TDF leads to changes in absolute haemoglobin at 24 weeks.

Critère d'inclusion

  • Human Immunodeficiency Virus (HIV-1) Infection

Liens